Kenvue Inc. (NYSE:KVUE) Position Trimmed by Community Bank N.A.

Community Bank N.A. lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 14.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,553 shares of the company's stock after selling 12,819 shares during the quarter. Community Bank N.A.'s holdings in Kenvue were worth $1,763,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. SRS Capital Advisors Inc. lifted its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Clarity Asset Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter worth approximately $45,000. SBI Securities Co. Ltd. acquired a new stake in shares of Kenvue during the fourth quarter worth approximately $46,000. Deseret Mutual Benefit Administrators grew its position in Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after purchasing an additional 568 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Kenvue by 77.9% during the first quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock valued at $82,000 after purchasing an additional 1,495 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

KVUE opened at $21.45 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market cap of $41.15 billion, a PE ratio of 38.99, a price-to-earnings-growth ratio of 3.36 and a beta of 0.98. The stock has a 50-day moving average of $23.03 and a 200-day moving average of $22.46. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period in the previous year, the company earned $0.28 EPS. The company's revenue for the quarter was down 3.9% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on KVUE shares. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Barclays lifted their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research note on Friday. Finally, Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.